ABOUT THE SERVICE
Brii Biosciences’ monoclonal antibody combination therapy, BRII-196/BRII-198, is designed to neutralize SARS-CoV-2 and provide a treatment option for non-hospitalized COVID-19 patients at high risk of clinical progression to severe disease. It received approval from the NMPA in China.
Information is owner-confirmed
Last updated 4 months ago
Price range
Other products/services from Brii Biosciences
BRII-179 (VBI-2601)
Biotechnology
N/A
Brii Biosciences
United States (US)